Description:
An impurity of Irinotecan, a Topoisomerase I inhibitor used for the treatment of colon cancer and small cell lung cancer. It inhibits DNA and RNA synthesis with IC50s of 0.077 and 1.3 μM, respectively.
- Molecular Weight: 392.40
- Molecular Formula: C22H20N2O5
Purity: ≥95%
Canonical SMILES:
CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)O
InChI:
InChI=1S/C22H20N2O5/c1-3-12-13-7-11(25)5-6-17(13)23-19-14(12)9-24-18(19)8-16-15(20(24)26)10-29-21(27)22(16,28)4-2/h5-8,25,28H,3-4,9-10H2,1-2H3/t22-/m0/s1
InChIKey: FJHBVJOVLFPMQE-QFIPXVFZSA-N
- Boiling Point: 810.3±65.0°C (Predicted)
- Melting Point: >169°C (dec.)
- Solubility: Soluble in DMSO (Slightly, Sonicated), Methanol (Slightly, Heated, Sonicated)
- Appearance: Light green powder
- Application: the treatment of colorectal cancer
- Storage: Store at -20°C
Synonyms:
(4S)-4,11-Diethyl-4,9-dihydroxy-1H-pyrano[3',4': 6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)dione; 10-Hydroxy-7-ethylcamptothecin; SN 38 Lactone; Irinotecan EP Impurity E; SN-38; USP Irinotecan Related Compound B; Irinotecan Related Compound B; Irinotecan EP Impurity E; NSC-673596
More details are to be found on supplier website
